Surgery Partners Inc (SGRY)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $3.53B
Last updated: Nov 17, 2026 at 11:06 AM ET
Surgery Partners Inc (SGRY) Earnings: Report Dates and Results
Surgery Partners (SGRY) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Surgery Partners reported EPS of $0.12, above the -$0.13 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SGRY has an expected report date of Mar 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 66.7% above the $0.12 reported for the quarter ended Dec 31, 2025.
SGRY Earnings Call
The latest SGRY earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 40 quarters below that had an estimate, SGRY beat 20 and missed 20. Revenue for the quarter ended Sep 30, 2026 was $815.30M, down 0.8% from $821.50M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.12 | -$0.13 | N/A | +192.31% | Beat | -7.7% | 5 | 1 up, 0 down | Nov 9, 2026 | $815.30M |
| Jun 30, 2026 | $0.07 | -$0.03 | N/A | +333.33% | Beat | -58.8% | 11 | 0 up, 0 down | Aug 10, 2026 | $848.90M |
| Mar 31, 2026 | -$0.03 | -$0.14 | -$0.24 - -$0.06 | +78.57% | Beat | -175.0% | 10 | 0 up, 1 down | May 5, 2026 | $810.90M |
| Dec 31, 2025 | $0.12 | $0.30 | $0.19 - $0.35 | -60.50% | Miss | -72.7% | 9 | 0 up, 9 down | Mar 2, 2026 | $885.00M |
| Sep 30, 2025 | $0.13 | $0.16 | $0.10 - $0.25 | -18.75% | Miss | -31.6% | 11 | 0 up, 2 down | Nov 10, 2025 | $821.50M |
| Jun 30, 2025 | $0.17 | $0.14 | $0.02 - $0.24 | +21.43% | Beat | -19.0% | 11 | 0 up, 9 down | Aug 5, 2025 | $826.20M |
| Mar 31, 2025 | $0.04 | $0.05 | $0.00 - $0.11 | -20.00% | Miss | -60.0% | 10 | 0 up, 3 down | May 12, 2025 | $776.00M |
| Dec 31, 2024 | $0.44 | $0.38 | $0.25 - $0.46 | +16.74% | Beat | 0.0% | 12 | 0 up, 1 down | Mar 3, 2025 | $864.40M |
| Sep 30, 2024 | $0.19 | $0.26 | $0.16 - $0.34 | -26.92% | Miss | 0.0% | 13 | 0 up, 0 down | Nov 12, 2024 | $770.40M |
| Jun 30, 2024 | $0.21 | $0.20 | $0.12 - $0.22 | +5.00% | Beat | -25.0% | 11 | 0 up, 0 down | Aug 6, 2024 | $762.10M |
| Mar 31, 2024 | $0.10 | $0.08 | $0.02 - $0.12 | +25.00% | Beat | +25.0% | 10 | 0 up, 0 down | May 7, 2024 | $717.40M |
| Dec 31, 2023 | $0.44 | $0.38 | $0.32 - $0.42 | +15.79% | Beat | +63.0% | 10 | 0 up, 0 down | Feb 26, 2024 | $735.40M |
| Sep 30, 2023 | $0.19 | $0.15 | $0.10 - $0.34 | +26.67% | Beat | N/A | 10 | 1 up, 0 down | Nov 7, 2023 | $674.10M |
| Jun 30, 2023 | $0.28 | $0.08 | $0.03 - $0.11 | +250.00% | Beat | N/A | 11 | 0 up, 1 down | Aug 1, 2023 | $667.60M |
| Mar 31, 2023 | $0.08 | $0.01 | -$0.04 - $0.09 | +700.00% | Beat | N/A | 9 | 0 up, 0 down | May 1, 2023 | $666.20M |
| Dec 31, 2022 | $0.27 | $0.18 | $0.08 - $0.28 | +50.00% | Beat | +17.4% | 9 | 0 up, 0 down | Mar 1, 2023 | $707.10M |
| Sep 30, 2022 | -$0.02 | $0.05 | -$0.03 - $0.15 | -140.00% | Miss | N/A | 8 | 0 up, 0 down | Nov 8, 2022 | $620.60M |
| Jun 30, 2022 | -$0.03 | -$0.02 | -$0.07 - $0.06 | -50.00% | Miss | N/A | 8 | 0 up, 0 down | Aug 2, 2022 | $615.40M |
| Mar 31, 2022 | -$0.09 | -$0.06 | -$0.13 - -$0.01 | -50.00% | Miss | N/A | 8 | 0 up, 0 down | May 3, 2022 | $596.20M |
| Dec 31, 2021 | $0.23 | $0.19 | $0.05 - $0.31 | +21.05% | Beat | +155.6% | 9 | 0 up, 0 down | Feb 28, 2022 | $610.20M |
| Sep 30, 2021 | -$0.05 | -$0.10 | -$0.42 - $0.01 | +50.00% | Beat | N/A | 8 | N/A | Nov 2, 2021 | $559.20M |
| Jun 30, 2021 | $0.00 | -$0.15 | -$0.39 - -$0.13 | +98.93% | Beat | N/A | 5 | N/A | Aug 4, 2021 | $543.30M |
| Mar 31, 2021 | -$0.30 | -$0.39 | -$0.55 - -$0.14 | +23.08% | Beat | N/A | 4 | N/A | May 5, 2021 | $512.40M |
| Dec 31, 2020 | $0.09 | $0.02 | -$0.21 - $0.17 | +350.00% | Beat | -35.7% | 6 | N/A | Mar 10, 2021 | $548.30M |
| Sep 30, 2020 | -$0.53 | -$0.34 | -$0.57 - -$0.17 | -55.88% | Miss | N/A | 5 | N/A | Nov 4, 2020 | $496.10M |
| Jun 30, 2020 | -$0.48 | -$0.74 | -$0.96 - -$0.41 | +35.14% | Beat | N/A | 6 | N/A | Aug 5, 2020 | $374.70M |
| Mar 31, 2020 | -$0.34 | -$0.48 | -$0.67 - -$0.14 | +29.17% | Beat | N/A | 5 | N/A | May 11, 2020 | $441.00M |
| Dec 31, 2019 | $0.14 | $0.17 | -$0.03 - $0.27 | -17.65% | Miss | N/A | 7 | N/A | Mar 5, 2020 | $517.20M |
| Sep 30, 2019 | -$0.28 | -$0.18 | -$0.36 - -$0.11 | -55.56% | Miss | N/A | 6 | N/A | Nov 5, 2019 | $452.00M |
| Jun 30, 2019 | -$0.29 | -$0.15 | -$0.36 - -$0.01 | -93.33% | Miss | N/A | 8 | N/A | Aug 7, 2019 | $445.40M |
| Mar 31, 2019 | -$0.42 | -$0.25 | -$0.46 - -$0.08 | -68.00% | Miss | N/A | 9 | N/A | May 8, 2019 | $416.80M |
| Dec 31, 2018 | -$0.17 | $0.12 | -$0.13 - $0.35 | -241.67% | Miss | N/A | 8 | N/A | Mar 13, 2019 | $491.20M |
| Sep 30, 2018 | -$0.19 | -$0.08 | -$0.32 - $0.24 | -137.50% | Miss | N/A | 7 | N/A | Nov 7, 2018 | $432.40M |
| Jun 30, 2018 | -$0.18 | -$0.15 | -$0.31 - $0.16 | -20.00% | Miss | N/A | 7 | N/A | Aug 9, 2018 | $436.60M |
| Mar 31, 2018 | -$0.26 | -$0.18 | -$0.22 - $0.02 | -44.44% | Miss | -750.0% | 6 | N/A | May 9, 2018 | $411.30M |
| Dec 31, 2017 | -$0.59 | $0.07 | $0.01 - $0.15 | -942.86% | Miss | -410.5% | 5 | N/A | Mar 1, 2018 | $460.35M |
| Sep 30, 2017 | -$0.02 | -$0.06 | -$0.21 - $0.03 | +66.67% | Beat | -109.5% | 8 | N/A | Nov 8, 2017 | $282.68M |
| Jun 30, 2017 | -$0.01 | $0.19 | $0.15 - $0.22 | -105.26% | Miss | -106.3% | 8 | N/A | Aug 8, 2017 | $288.35M |
| Mar 31, 2017 | $0.04 | $0.07 | N/A | -42.86% | Miss | -20.0% | N/A | N/A | May 9, 2017 | $286.18M |
| Dec 31, 2016 | $0.19 | $0.20 | N/A | -5.00% | Miss | N/A | N/A | N/A | Mar 9, 2017 | $306.00M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.46, down 51.1% from the year before. It was $0.61 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.46 | -51.1% |
| Dec 31, 2024 | $0.94 | -5.1% |
| Dec 31, 2023 | $0.99 | +661.5% |
| Dec 31, 2022 | $0.13 | N/A |
| Dec 31, 2021 | -$0.12 | N/A |
| Dec 31, 2020 | -$1.26 | N/A |
| Dec 31, 2019 | -$0.85 | N/A |
| Dec 31, 2018 | -$0.80 | N/A |
| Dec 31, 2017 | -$0.58 | -195.1% |
| Dec 31, 2016 | $0.61 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 7,800 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 7,814 | 14 | |
| 2026Q1 | Mar 31, 2026 | 6,929 | 15 | |
| 2025Q4 | Dec 31, 2025 | 1,863 | 3 | |
| 2025Q3 | Sep 30, 2025 | 6,555 | 8 | |
| 2025Q2 | Jun 30, 2025 | 8,637 | 13 | |
| 2025Q1 | Mar 31, 2025 | 7,427 | 14 | |
| 2024Q4 | Dec 31, 2024 | 10,312 | 12 | |
| 2024Q3 | Sep 30, 2024 | 6,381 | 14 |
2026Q2 Earnings Call
Opening remarks
David Doherty Chief Financial Officer Good morning, and thank you for joining Surgery Partners' Second Quarter 2026 Earnings Call. I'm joined today by Eric Evans, our Chief Executive Officer; and Justin Oppenheimer, our Chief Operating Officer. During this call, we will make forward-looking statements. There are risk factors that could cause future results to be materially different from these statements as described in this morning's press release and in the reports we file with the SEC. The company does not undertake any duty to update these forward-looking statements. In addition, we will reference certain non-GAAP financial measures, which we believe can be useful in evaluating our performance. We have reconciled these measures to the applicable GAAP measures in this morning's press release and in the supplemental materials posted to our Investor Relations website. With that, I will turn the call over to Eric Evans. Eric?
Eric Evans Chief Executive Officer Thank you, Dave, and good morning, everyone. Before discussing our quarterly results, I want to address a significant portfolio optimization milestone we announced last month. As we noted, we have signed definitive agreements in escrow for the sale of our interest in the Idaho Falls market, Mountain View Hospital and Idaho Falls Community Hospital to our partner, Intermountain Health. We have had a successful and long-standing partnership with Intermountain, not only in Idaho, but also in 15 ASCs across Utah and Montana that remain in our portfolio. The Idaho Falls facilities have built an exceptional reputation as preferred providers and leaders in delivering high-quality, affordable care for the Idaho Falls region. At the same time, they have evolved in ways that today extend well beyond our core short-stay surgical focus to include more traditional acute care services such as obstetrics, neonatology, pediatrics and other nonsurgical service lines. We are confident these facilities will continue to grow and serve the health care needs of this community with the strength of Intermountain's partnership. This pending transaction is the most impactful part of our strategic review process to date and represents the vast majority of planned portfolio optimization. Our objectives in this process were to further sharpen our focus on our core short-stay surgical facility portfolio to simplify our operations, drive growth and strengthen our balance sheet, and we believe we have been successful in achieving this. To help investors evaluate the company on a comparable basis, in the supplemental financial information we posted on our Investor Relations website this morning, we provide key financial and nonfinancial metrics about this market to help illustrate the change in our business mix, assuming this transaction closes. Dave will speak to the transaction financials in greater detail shortly.
Frequently Asked Questions About SGRY
When is Surgery Partners's next earnings date?
Surgery Partners's next earnings report is expected for Mar 1, 2027.
Did SGRY beat earnings estimates last quarter?
Yes. Surgery Partners reported EPS of $0.12 for the quarter ended Sep 30, 2026, above the -$0.13 estimate, a 192.31% surprise.
What EPS do analysts expect from SGRY next quarter?
The consensus EPS estimate for Surgery Partners for the quarter ending Dec 31, 2026 is $0.20 from 10 analysts, with estimates from $0.12 to $0.33.
How often does SGRY beat earnings estimates?
Surgery Partners beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +67.89%.
SGRY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors